A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Clinical trial NCT02957032 · TERMINATED
Trial details
- NCT number
- NCT02957032
- Sponsor
- Philogen S.p.A.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-04-13
- Primary completion
- 2023-09-29
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.